Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 31472914)

  • 1. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma.
    Sadeghi S; Bejjani A; Finn RS
    Surg Oncol Clin N Am; 2019 Oct; 28(4):695-715. PubMed ID: 31472914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
    Chung V
    Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
    Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
    Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Milestones in the pathogenesis and management of primary liver cancer.
    Nault JC; Cheng AL; Sangro B; Llovet JM
    J Hepatol; 2020 Feb; 72(2):209-214. PubMed ID: 31954486
    [No Abstract]   [Full Text] [Related]  

  • 5. Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy?
    Parks AL; McWhirter RM; Evason K; Kelley RK
    J Gastrointest Cancer; 2015 Jun; 46(2):161-5. PubMed ID: 25662892
    [No Abstract]   [Full Text] [Related]  

  • 6. Novel targeted treatment options for advanced cholangiocarcinoma.
    Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
    Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.
    Zhou G; Boor PPC; Bruno MJ; Sprengers D; Kwekkeboom J
    Br J Cancer; 2022 Jan; 126(1):10-23. PubMed ID: 34400801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics of hepatobiliary carcinogenesis.
    Nault JC; Zucman-Rossi J
    Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for cholangiocarcinoma: a 2021 update.
    Charalampakis N; Papageorgiou G; Tsakatikas S; Fioretzaki R; Kole C; Kykalos S; Tolia M; Schizas D
    Immunotherapy; 2021 Sep; 13(13):1113-1134. PubMed ID: 34190581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapies for intrahepatic cholangiocarcinoma.
    Kelley RK; Bridgewater J; Gores GJ; Zhu AX
    J Hepatol; 2020 Feb; 72(2):353-363. PubMed ID: 31954497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does aspirin use influence hepatocellular carcinoma and cholangiocarcinoma prognosis?
    Stefanini B; Tonnini M; Marseglia M; Tovoli F
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):887-889. PubMed ID: 35866267
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
    Zhang Q; Lou Y; Bai XL; Liang TB
    World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Systemic treatment of liver and biliary tumors].
    Malek NP; Greten T; Kubicka S
    Internist (Berl); 2007 Jan; 48(1):46-9. PubMed ID: 17177032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
    Herraez E; Lozano E; Macias RI; Vaquero J; Bujanda L; Banales JM; Marin JJ; Briz O
    Hepatology; 2013 Sep; 58(3):1065-73. PubMed ID: 23532667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs.
    Sipra QUAR; Shroff R
    Expert Opin Investig Drugs; 2021 Apr; 30(4):281-284. PubMed ID: 33228417
    [No Abstract]   [Full Text] [Related]  

  • 16. Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver.
    Hewitt DB; Rahnemai-Azar AA; Pawlik TM
    Expert Opin Investig Drugs; 2021 Aug; 30(8):827-835. PubMed ID: 34102935
    [No Abstract]   [Full Text] [Related]  

  • 17. Alterations in DNA Damage Repair Genes in Primary Liver Cancer.
    Lin J; Shi J; Guo H; Yang X; Jiang Y; Long J; Bai Y; Wang D; Yang X; Wan X; Zhang L; Pan J; Hu K; Guan M; Huo L; Sang X; Wang K; Zhao H
    Clin Cancer Res; 2019 Aug; 25(15):4701-4711. PubMed ID: 31068370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs.
    Marin JJ; Macias RI
    Expert Opin Investig Drugs; 2021 Jul; 30(7):675-679. PubMed ID: 33934687
    [No Abstract]   [Full Text] [Related]  

  • 19. Biomarkers for Hepatobiliary Cancers.
    Nault JC; Villanueva A
    Hepatology; 2021 Jan; 73 Suppl 1():115-127. PubMed ID: 32045030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetics and targeted therapeutics in biliary tract carcinoma.
    Marks EI; Yee NS
    World J Gastroenterol; 2016 Jan; 22(4):1335-47. PubMed ID: 26819503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.